Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Neoplasms 1Neoplasm Metastasis 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × Epothilones × Clear all
NCT00080301 2020-11-02

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

R-Pharm

Phase 3 Completed
752 enrolled 22 charts
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00082433 2020-11-02

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

R-Pharm

Phase 3 Completed
1,221 enrolled 18 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡